[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650405":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":39,"responsibleParty":44,"collaborators":39,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":39,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":39,"enrollmentInfo":54,"targetDuration":39,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":39,"overallStatus":64,"whyStopped":39,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},{"fullName":5,"class":6},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulation Group","EXPERIMENTAL","Rivaroxaban 15mg once daily, or Edoxaban 30mg once daily, or Apixaban 2.5mg twice daily, or Dabigatran 110mg twice daily",[13],"Drug: Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran",{"label":15,"type":6,"description":16,"interventionNames":17},"Anti-platelet Group","Aspirin 100mg once daily, or alternatives (Clopidogrel 75mg once daily, Ticagrelor 90mg twice daily, Cilostazol 100mg twice daily) if aspirin is unsuitable",[18],"Drug: Aspirin",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran",[9],[25],"Anticoagulation Therapy",{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":29},"Aspirin",[15],[30],"Anti-platelet therapy",[32],{"name":33,"affiliation":5,"role":34},"Min Lou, PhD, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","8613958007213",null,"lm99@zju.edu.cn",{"name":42,"role":37,"phone":43,"phoneExt":39,"email":40},"Kemeng Zhang, MD","8617816860685",{"type":45,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100650405","phase-3-study-on-anti-thrombotic-regimens-for-secondary-prevention-in-ischemic-stroke-patients-with-possible-benefit-from-anticoagulation-therapy-100650405",false,"NCT07746882","Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy","Inclusion Criteria:\n\n* Age ≥18 years\n* Ischemic stroke patients with undetermined etiology, within 14 days of onset, with completed etiological assessment\n* At least one of the following:\n\n  1. Cortical or multi-territorial infarct\n  2. Recurrent stroke or stroke on antiplatelet therapy\n  3. Left atrial diameter \\>40 mm\n  4. Left ventricular dysfunction (EF 30-40% or regional wall motion abnormality)\n  5. Atrial premature beats \\>1500\u002F24h\n\nExclusion Criteria:\n\n* Stenosis ≥50% in the responsible vessel or high-risk plaque\n* Identified cardioembolic source\n* PFO with planned closure\n* Malignancy\n* Indication for mandatory anticoagulation\u002Fantiplatelet therapy\n* Active bleeding (intracranial, subarachnoid, gastrointestinal, etc.)\n* History of intracranial hemorrhage\n* Current or recent gastrointestinal ulcer\n* Recent brain or spinal injury\u002Fsurgery\n* Known or suspected vascular malformations or aneurysms\n* Severe renal impairment (CrCl \\\u003C30 ml\u002Fmin)\n* Liver disease with bleeding risk (Child-Pugh B or C)\n* Pregnancy or lactation\n* Other contraindications to anticoagulation","ALL","18 Years",{"count":55,"type":56},680,"ESTIMATED","INTERVENTIONAL",[59],"PHASE3","To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.",[62,63],"Stroke","Acute Ischemic Stroke","NOT_YET_RECRUITING","2026-08-04",{"date":67,"type":68},"2026-08-05","ACTUAL",{"date":70,"type":56},"2026-08-15",{"date":72,"type":56},"2028-11-30",{"name":5,"class":6}]